No Data
No Data
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Former senior official of the Japan Financial Services Agency: There may be another rate hike before the end of the year!
Former senior official Tomoko Amaya of the Japan Ministry of Finance said that the central bank may raise interest rates again before the end of the year; she said that what matters is not the level or volatility of stock prices, but the level of confidence. The stable recovery of the market is enough to make interest rate hikes possible this year.
Emerging market stock digest: Karada Note temporarily hits the upper limit, Unipos hits the upper limit.
<5616> Rain, Wind, Sun 1099 -112 Sharp drop. The Tokyo Stock Exchange announced on the 6th that the initial margin rate for margin trading of the company's shares would be set at over 50% (including over 20% in cash), leading to predominant selling pressure due to aversion to this. Additionally, the Japan Securities Finance implemented an increase in collateral collection measures, setting the collateral rate for own account transactions and non-clearing participants' settlement transactions at 50% (including 20% in cash collateral) from that day onwards.
Hot stocks Digest (morning session): Koseido HD, Good Design Company, Medorec, etc.
Ryohin Keikaku <7453>: 2,699 yen (+80.5 yen) rebounded significantly. Despite the previous day's decision not to adopt the Nikkei average, there was a prevailing sense of short-term exhaustion, but today there is a dominant movement once again expecting short-term improvements in supply and demand. Furthermore, SMBC Nikko Securities continues to maintain an investment rating of "1" and has raised the target stock price from 3,100 yen to 3,600 yen. Expecting the continued strong performance of high-gross-profit-margin household goods, it is also evaluating that there is still significant room for improvement in midterm adjustments.
SBI Biotech - Continued decline, favorable analysis results of Phase 2 trial of major development product SB623 published in Neurology journal
The stock continued to decline. After the close of trading on the 5th, it announced that the results of the Phase 2 STEMTRA trial of the main development product SB623 were published in Neurology journal. The Phase 2 multicenter cooperative sham surgery-controlled randomized double-blind comparative trial (STEMTRA trial) aimed to investigate the effectiveness and safety of the main development product SB623 in patients with chronic motor function disorders caused by traumatic brain injury conducted from 2016 to 2019, until the 48th week (final).
SanBio Updates on Development of SB623 Drug for Chronic Effects of Traumatic Brain Injury
No Data
No Data